Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

Basit Öğe Kaydı
dc.contributor.authorSaydam, Güray
dc.contributor.authorHaznedaroglu, Ibrahim Celalettin
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorYavuz, Akif S.
dc.contributor.authorAli, Ridvan
dc.contributor.authorGuvenc, Birol
dc.contributor.authorAkay, Olga M.
dc.contributor.authorBaslar, Zafer
dc.contributor.authorOzbek, Ugur
dc.contributor.authorSonmez, Mehmet
dc.contributor.authorAydin, Demet
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorUndar, Bulent
dc.contributor.authorDagdas, Simten
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorAkkaynak, Diyar Z.
dc.contributor.authorDag, Ilkiz M.
dc.contributor.authorIlhan, Osman
dc.date.accessioned2019-10-27T11:26:07Z
dc.date.available2019-10-27T11:26:07Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL10.1% on the International Scale [BCR-ABL1(IS)]) by 12months.Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300mg twice daily. This analysis was based on the first 12months of follow-up in a 24-month study.Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1(IS) 0.0032%) by 12months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP.en_US
dc.description.sponsorshipNovartis Pharmaceuticals CorporationNovartisen_US
dc.description.sponsorshipThis study was funded by Novartis Pharmaceuticals Corporation.en_US
dc.identifier.doi10.1080/14656566.2016.1219338en_US
dc.identifier.endpage1858en_US
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.issue14en_US
dc.identifier.pmid27501474en_US
dc.identifier.startpage1851en_US
dc.identifier.urihttps://doi.org/10.1080/14656566.2016.1219338
dc.identifier.urihttps://hdl.handle.net/11454/33460
dc.identifier.volume17en_US
dc.identifier.wosWOS:000384401200003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBCR-ABL1en_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjectmolecular responseen_US
dc.subjectnilotiniben_US
dc.subjecttyrosine kinase inhibitoren_US
dc.titleOutcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phaseen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu